Uterine Fibroid Treatment Device Market Forecast And Competitive Strategies Report 2025-2033

(MENAFN- GlobeNewsWire - Nasdaq) The market opportunities in the global uterine fibroid treatment device sector include rising demand for minimally invasive treatments, increasing prevalence and diagnosis of uterine fibroids, expanding awareness and fertility-preserving solutions. Growth prospects are significant in Asia-Pacific due to better healthcare access and rising incomes.

Dublin, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The "Uterine Fibroid Treatment Device Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033" has been added to ResearchAndMarkets's offering.

The global market for uterine fibroid treatment devices is predicted to grow at a CAGR of 7.0% from 2025 to 2033. This growth is fueled by a rising occurrence of uterine fibroids among women of reproductive age, a surging demand for minimally invasive and non-invasive treatments, and enhanced awareness of complications like infertility, heavy bleeding, and pelvic pain. Healthcare providers play a pivotal role in this trend, focusing on enhancing patient outcomes and minimizing hospital stays, leading to increased demand for innovative fibroid management technologies worldwide.

Market Drivers

Increasing Preference for Minimally and Non-Invasive Treatment Options: Globally, interest is shifting towards treatment options for uterine fibroids that promise reduced recovery times, lower complication rates, and preservation of fertility. Techniques such as laparoscopic myomectomy, MR-guided focused ultrasound (MRgFUS), and uterine artery embolization (UAE) are becoming popular alternatives to traditional hysterectomies. Heightened awareness and improved reimbursement processes are boosting the adoption of less-invasive devices, particularly in outpatient and ambulatory surgical settings.

Rising Prevalence and Awareness of Uterine Fibroids: It is estimated that up to 70-80% of women develop fibroids by age 50, though treatment is necessary only for some. Increased use of pelvic imaging and proactive gynecological consultations are expanding the pool of patients eligible for device-based treatments. Additionally, patient awareness campaigns in association with medical organizations are promoting earlier intervention, especially for women prioritizing uterine preservation and fertility outcomes.

Market Restraint

High Cost and Limited Access: Despite clinical advantages, high costs of advanced treatment systems pose a significant barrier, especially in developing regions. The availability of trained specialists and adequate infrastructure is limited, hindering the broader adoption of device-based uterine fibroid therapies in underserved areas.

Market Segmentation by Technology

The market is divided by technology into Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, and Embolization Techniques. In 2024, surgical techniques like myomectomy and hysterectomy remained dominant. However, laparoscopic and ablation techniques are expected to grow rapidly through 2033, driven by advances in minimally invasive devices, real-time imaging, and robotics. Embolization, such as UAE, is gaining acceptance as a non-surgical intervention.

Market Segmentation by Treatment Type

By treatment type, the market includes Invasive, Minimally Invasive, and Non-Invasive Treatments. In 2024, minimally invasive treatments dominated due to patient preference for uterus-sparing procedures. Non-invasive treatments like high-intensity focused ultrasound (HIFU) are projected to grow fastest, though currently limited to specialized centers. Invasive treatments, like hysterectomy, still hold a significant share where alternatives are less accessible or not reimbursed.

Geographic Trends

In 2024, North America led the uterine fibroid treatment device market due to advanced healthcare infrastructure and high diagnostic rates. Europe followed, with countries like Germany, the UK, and France expanding access to minimally invasive procedures. Asia-Pacific is projected to see the highest CAGR from 2025 to 2033, with advancing women's health awareness and infrastructure developments. Latin America and MEA display potential through public-private partnerships in women's health care.

Competitive Trends

The market is moderately consolidated with leading companies like Hologic, Boston Scientific, and Johnson & Johnson focusing on innovation and global expansion. Medtronic, Conmed, and Karl Storz offer advanced laparoscopic tools, while Insightec and Nesa Medtech specialize in non-invasive ultrasound technologies. Minerva Surgical and CooperSurgical have a focus on endometrial ablation and intrauterine treatment systems. Strategies include product miniaturization and AI-powered guidance for precision and improved patient outcomes.

Companies Featured

• Boston Scientific
• Canyon Medical
• Conmed
• CooperSurgical
• Hologic
• Insightec
• Karl Storz
• Medtronic
• Merit Medical Systems
• Minerva Surgical
• Nesa Medtech
• Olympus
• Shenzhen Mindray Bio-Medical Electronics

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN24092025004107003653ID1110105712